The GMR for cycle 1 AUC comparisons (for DLBCL in Study GO29044 vs. DLBCL in Study GO27834) was 0.805 (90% CI 0.691–0.938) for acMMAE, and 0.907 (90% CI 0.629–1.31) for unconjugated MMAE, for pola + G-CHP compared with pola + obinutuzumab only (Table 2). The gene discussed is POLA1; the disease is diffuse large B-cell lymphoma.